Leesutton6201

Adjuvant chemotherapy was independently associated with improved 5-year OS (P < 0.001).

Age, comorbidities and adjuvant chemotherapy were independent predictors for OS. Resection of rectal tumors in fit elderly patients should be promoted; however, patients should be aware of the high risk of stoma. Geriatr Gerontol Int 2021; 21 670-675.

Age, comorbidities and adjuvant chemotherapy were independent predictors for OS. Resection of rectal tumors in fit elderly patients should be promoted; however, patients should be aware of the high risk of stoma. Geriatr Gerontol Int 2021; 21 670-675.

The number of patients with both chronic obstructive pulmonary disease (COPD) and heart failure (HF) is increasing in Asia, and these conditions often coexist. We previously revealed a tendency of beta-blocker underuse among patients with HF with reduced ejection fraction (HFrEF) and COPD in Asian countries other than Japan. Here, we evaluated the impact of cardio-selective beta-blocker use on the long-term outcomes of patients with HF and COPD.

Among the 5232 patients with HFrEF (left ventricular ejection fraction of <40%) prospectively enrolled from 11 Asian regions in the ASIAN-HF registry, 412 (7.9%) had a history of COPD. We compared the clinical characteristics and long-term outcomes of the patients with HF and COPD according to the use and type of beta-blockers used cardio-selective beta-blockers (n=149) vs. non-cardio-selective beta-blockers (n=124) vs. no beta-blockers (n=139). The heart rate was higher, and the outcome was poorer in the no beta-blocker group than in the beta-blocker groups. The 2year all-cause mortality was significantly lower in the non-cardio-selective beta-blocker group than in the no beta-blocker group. Further, the cardiovascular mortality significantly decreased in the non-cardio-selective beta-blocker group before (hazard ratio 0.36; 95% confidence interval 0.18-0.73; P=0.004) and after adjustments (hazard ratio 0.37; 95% confidence interval 0.19-0.73; P=0.005), but not in the cardio-selective beta-blocker group.

Beta-blockers reduced the all-cause mortality of patients with HFrEF and COPD after adjusting for age and heart rate, although the possibility of selection bias could not be completely excluded due to multinational prospective registry.

Beta-blockers reduced the all-cause mortality of patients with HFrEF and COPD after adjusting for age and heart rate, although the possibility of selection bias could not be completely excluded due to multinational prospective registry.

IMbrave150 is a phase III trial that assessed atezolizumab+bevacizumab (ATEZO/BEV) versus sorafenib (SOR) in patients with unresectable hepatocellular carcinoma (HCC) and demonstrated a significant improvement in clinical outcomes. Exploratory analyses characterized objective response rate (ORR), depth (DpR), and duration of response (DoR), and patients with a complete response (CR).

Patients were randomized 21 to intravenous ATEZO (1200mg)+BEV (15mg/kg) every 3weeks or oral SOR (400mg) twice daily. Tumors were evaluated using Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST 1.1) and HCC-modified RECIST (mRECIST). ORR by prior treatment and largest baseline liver lesion size, DoR, time to response (TTR), and complete response (TTCR) were analyzed.

For both criteria, responses favored ATEZO/BEV versus SOR regardless of prior treatment and in patients with lesions ≥3cm. Median TTR was 2.8months per RECIST 1.1 (range 1.2-12.3months) and 2.8months per mRECIST (range 1.1-12.3months) with ATEZO/BEV. Patients receiving ATEZO/BEV had a greater DpR, per both criteria, across baseline liver lesion sizes. Characteristics of complete responders were similar to those of the intent-to-treat population. In complete responders receiving ATEZO/BEV per mRECIST versus RECIST 1.1, respectively, median TTCR was shorter (5.5 vs. 7.0months), mean baseline sum of lesion diameter was longer (5.0 [SD, 5.1] vs. 2.6[SD, 1.4] cm), and mean largest liver lesion size was larger (4.8 [SD, 4.2] vs. 2.3[SD,1.0]cm).

These data highlight the improved ORR, DpR, and CR rates with ATEZO/BEV in unresectable HCC.

These data highlight the improved ORR, DpR, and CR rates with ATEZO/BEV in unresectable HCC.Nanomaterials having enzyme-like activities are recognized as potentially important self-therapeutic nanomedicines. Herein, a peroxidase-like artificial enzyme is developed based on novel biodegradable boron oxynitride (BON) nanostructures for highly efficient and multi-mode breast cancer therapies. The BON nanozyme catalytically generates cytotoxic hydroxyl radicals, which induce apoptosis of 4T1 cancer cells and significantly reduce the cell viability by 82% in 48 h. In vivo experiment reveals a high potency of the BON nanozyme for breast tumor growth inhibitions by 97% after 14-day treatment compared with the control, which are 10 times or 1.3 times more effective than the inert or B-releasing boron nitride (BN) nanospheres, respectively. This work highlights the BON nanozyme and its functional integrations within the BN nanomedicine platform for high-potency breast cancer therapies.Cancer-related fatigue (CRF) is one of the most common chronic symptoms experienced by cancer patients. Selleckchem NSC 167409 As moxibustion is a popular traditional therapy for managing fatigue, it can be an alternative strategy to treat CRF as well. Therefore, we rigorously designed a full-scale, multicenter, assessor-blinded, randomized controlled trial to evaluate the efficacy and safety of moxibustion treatment for CRF. Ninety-six subjects suffering from CRF were recruited and randomly assigned to moxibustion group, sham moxibustion group, or usual care group. Both the moxibustion group and the sham group received moxibustion treatment for 8 weeks and the usual care group did not. Brief fatigue inventory (BFI) score and Functional Assessment of Cancer Therapy-Fatigue score were used to assess CRF at baseline and weeks 5, 9, and 13. Questionnaires for the assessment of cognitive impairment, quality of life, and Cold-Heat and Deficiency-Excess patterns were also evaluated. BFI scores significantly decreased in moxibustion group compared to the usual care group (mean difference of -1.